United States The United States Food and Drug Administration orders manufacturers of GLP-1 medicines such as semaglutide and tirzepatide, originally intended for the treatment of type 2 diabetes but also commonly used for weight loss, to add warnings that use of such drugs may increase the risk of developing non-arteritic anterior ischemic optic neuropathy, an optic nerve disorder that can lead to permanent blindness. Sources: BBC News Reuters